Rush University researcher recognized for longitudinal studies on aging, memory, and dementia.
Researchers report a link between sleepiness and accelerated Aβ buildup in the cingulate and precuneus of elderly adults without dementia.
Voyager Therapeutics announced positive interim results from a small, ongoing Phase 1b trial in people with advanced PD.
Representing each cell as a point, the atlas could help scientists measure brain-wide cell numbers and activity in health and disease.
Two new papers strengthen the evidence that TREM2 protects against amyloid pathology.
A winter storm cut the meeting short, but not before attendees learned that viral load correlates with clinical and pathological traits of AD.
A CRISPR knockout screen in human cells and mouse neurons found genes that tweak C9ORF72 toxicity, zeroing in on ER stress as a potential therapeutic target.
After verubecestat’s demise, scientists ask if BACE inhibitor side effects could partly stem from the other BACE.
A new study tries to untangle the complex relationship between sleep and Aβ. It reports that the older healthy people who are most drowsy during the day accumulate amyloid faster than those who stay alert. The Aβ deposits primarily in the cingulate and precuneus, brain regions that amass amyloid plaques early in the progression of Alzheimer’s disease.
Two new papers strengthen the idea that the microglial receptor helps protect against Alzheimer’s disease. In one, an AD mouse model that overexpresses TREM2 had less plaque and maintained normal memory. In the other, researchers found that Aβ directly bound to the receptor, triggering microglia to activate and degrade the peptide. The studies suggest that TREM2 may direct the brain’s response to amyloid buildup, and that boosting it could help.
As the research community tries to meet the challenge of treating Alzheimer’s disease by 2025, the need for many more clinical study participants has reached a critical point. Using a crowdsourcing platform called Ideascale, the National Institute on Aging invites researchers, clinicians, site coordinators, caregivers, family members, people with dementia, and advocates to share their thoughts on how to boost awareness and recruitment of volunteers. Join the conversation.
- Adrian Danek on Wiping Out Microglia Prevents Neuritic Plaques
- Marcia Ratner on Merck Axes Verubecestat for Prodromal AD, Researchers Say ‘Go Earlier’
- Hugo Geerts on Boehringer Ingelheim Bails on Candidate Alzheimer’s Drug
- Simon Laws and Stephanie Rainey-Smith on Does Daytime Drowsiness Foreshadow Aβ Accumulation?
- Barbara Bendlin on Does Daytime Drowsiness Foreshadow Aβ Accumulation?
- Michel Goedert on Compact Mouse Brain Atlas: A New Tool for Studying Neurodegeneration?
- Nolwen Rey on Compact Mouse Brain Atlas: A New Tool for Studying Neurodegeneration?
- Johnathan Cooper-Knock on CRISPR Screen Pulls Down Fresh Targets for C9ORF72 ALS
- David Hansen on TREM2 Binds Aβ, Reprograms Microglia to Curb Plaques
- Jason Ulrich on TREM2 Binds Aβ, Reprograms Microglia to Curb Plaques
- Gernot Kleinberger on TREM2 Binds Aβ, Reprograms Microglia to Curb Plaques
- Rita Guerreiro on TREM2 Binds Aβ, Reprograms Microglia to Curb Plaques
- J. David Schaffer on CRISPR Screen Pulls Down Fresh Targets for C9ORF72 ALS
- Ludo Van Den Bosch on CRISPR Screen Pulls Down Fresh Targets for C9ORF72 ALS
- Robert Baloh on CRISPR Screen Pulls Down Fresh Targets for C9ORF72 ALS
- Sabrina Paganoni on FDA OKs Cognition as Sole Outcome Measure for Preclinical AD Trials
- Philip Wong on Remember: BACE2 Is in the Brain, Too
- Douglas Galasko on Remember: BACE2 Is in the Brain, Too
- Gary Landreth on Wiping Out Microglia Prevents Neuritic Plaques
- Diego Gómez-Nicola on Wiping Out Microglia Prevents Neuritic Plaques
- Charles Glabe on Are Intraneuronal Aβ Oligomers ‘Seeding Units’ of Alzheimer’s Disease?